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Targeted Deficiency or Cytosolic Truncation of the
VE-cadherin Gene in Mice Impairs VEGF-Mediated
Endothelial Survival and Angiogenesis
cadherins (Hynes, 1992; Kemler, 1992; Gumbiner, 1996).
Endothelial cells contain VE-cadherin, only found at en-
dothelial adherens junctions (Lampugnani et al., 1992),
and N-cadherin, which is not clustered at cell±cell con-
tacts (Salomon et al., 1992) and is also present in other
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Vascular endothelial cadherin, VE-cadherin, mediates In the mouse, VE-cadherin is expressed in hemangio-
adhesion between endothelial cells and may affect blasts from day 7.5 of gestation (E7.5) onward (Breier et
vascular morphogenesis via intracellular signaling, but al., 1996) and, thereafter, constitutively in all endothelial
the nature of these signals remains unknown. Here, cells. Deficiency of VE-cadherin prevented organization
targeted inactivation (VEC2/2) or truncation of the of endothelial cells in vessel-like patterns in embryoid
b-catenin-binding cytosolic domain (VECdC/dC) of the bodies (Vittet et al., 1997).
VE-cadherin gene was found not to affect assembly In order to define the role of VE-cadherin and of its
of endothelial cells in vascular plexi, but to impair their binding to b-catenin in intracellular signaling, mice were
subsequent remodeling and maturation, causing le- generated that lacked a functional VE-cadherin gene
thality at 9.5 days of gestation. Deficiency or truncation (VEC2/2), that expressed a mutant VE-cadherin gene
of VE-cadherin induced endothelial apoptosis and lacking the b-catenin-binding cytoplasmic tail (VECdC/dC),
abolished transmission of the endothelial survival sig- or that did not express detectable VE-cadherin levels
nal by VEGF-A to Akt kinase and Bcl2 via reduced com- because of an intronic neomycin phosphotransferase
plex formation with VEGF receptor-2, b-catenin, and (neo) gene (VECneo/neo). Surprisingly, all three strains died
phosphoinositide 3 (PI3)-kinase. Thus, VE-cadherin/ at E9.5 due to vascular insufficiency, caused by in-
b-catenin signaling controls endothelial survival. creased endothelial apoptosis. Deficiency or truncation
of VE-cadherin blocked the capacity of endothelial cells
to respond to survival signals induced by vascular endo-Introduction
thelial growth factor type A (VEGF-A), by preventing forma-
tion of a complex consisting of VE-cadherin, b-catenin,Endothelial cells are linked to each other by tight- and
phosphoinositide-3-OH kinase (PI3-K), and VEGF recep-adherens-type junctions. The latter are formed by trans-
tor-2 (VEGFR-2/Flk1/KDR). As a result, VEGF-A did notmembrane calcium-dependent adhesive proteins, called
activate the serine/threonine protein kinase Akt (protein
kinase B) and did not increase levels of Bcl2, both medi-7 To whom correspondence should be addressed (e-mail: peter.
carmeliet@med.kuleuven.ac.be). ators of the antiapoptotic machinery (Nunez and del
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Figure 1. Targeting of the VE-cadherin Gene
(a) The truncation vector (pPNT.VECdC), the VECWT allele, the targeted allele containing a floxed intronic neo-cassette (VECneo) and the truncated
(VECdC) allele are shown.
(b) The inactivation vector (pPNT.VECnull), the wild type (VECWT), and the inactivated (VECnull) allele are shown. Numbered exons (darkened
blocks), introns (gray shaded bars), probes (lettered black boxes), restriction fragments (thin lines), novel restriction sites introduced by cloning,
VEC-numbered PCR primers (arrows); STOP (termination codon introduced for truncation); TAG (endogenous termination codon of VECWT).
The b-catenin binding domain in exon 12 is located between the STOP and TAG.
(c and d) Southern blot of SacI-digested genomic DNA hybridized with probe C, generating a 7 kb VECWT and a 12 kb VECnull fragment (c),
and of XbaI-digested DNA, hybridized with probe C, generating a 9 kb VECWT, a 3.1 kb VECneo, and a 1.1 kb VECdC fragment (d).
(e and f) Western blotting of E9.0 embryos for VE-cadherin (e) or immortalized endothelial cells for VE-cadherin, b-catenin, and pancadherin
(recognizing the cytoplasmic domain of VE-cadherin and N-cadherin) (f). Numbers in (f) indicate position of native VE-cadherin (1; Mr z116
kDa), truncated VE-cadherin (2; Mr z97 kDa), b-catenin (3; Mr z92 kDa), and N-cadherin (4; Mr z135 kDa).
Peso, 1998). Interestingly, VE-cadherin was required for deleted (Figure 1b). VEC1/neo ES cells were reelectropor-
ated with Cre-recombinase to remove neo (VEC1/dC). ESthe survival signal of VEGF-A, but not of basic fibroblast
cells homozygous for the inactivated VE-cadherin allelegrowth factor (bFGF). Thus, the present targeting study
(VEC2/2), the truncated VE-cadherin allele containingunveils a novel antiapoptotic pathway in endothelial
neo (VECneo/neo), and the truncated VE-cadherin allelecells, depending on intracellular signals via a pathway
without neo (VECdC/dC) were obtained by high neomycininvolving an endothelial adhesion molecule and a growth
(G418) selection. Correct targeting was confirmed byfactor receptor.
Southern blotting (Figures 1c and 1d) and PCR analysis
(not shown). Expression of VE-cadherin in embryos, in
Results endothelial cells purified from differentiated ES cells,
or in immortalized endothelial cells was comparable in
Targeted Inactivation and Truncation VEC1/1, VEC1/dC, and VECdC/dC cells, whereas VE-cad-
of the VE-cadherin Gene herin levels were z50% of normal in VEC1/2 and VEC1/neo
Truncation of the VE-cadherin gene was achieved by cells and undetectable in VEC2/2 and VECneo/neo endothe-
introducing a stop codon in front of the 82 carboxy- lial cells (Figures 1e and 1f). The undetectable expres-
terminal residues, interacting with b-catenin (Navarro et sion in VECneo/neo cells suggests that the intronic neo
al., 1998), and by incorporating an intronic neo cassette, cassette aborted VE-cadherin expression.
flanked by loxP sites (VEC1/neo; Figure 1a). For inactiva- Healthy VEC1/neo, VEC1/2, and VEC1/dC mice, the latter
obtained by crossbreeding VEC1/neo mice with pgk:cretion of the VE-cadherin gene (VEC1/2), exons 3 to 7 were
VE-Cadherin and VEGF-Induced Endothelial Survival
149
Figure 2. Abnormal Vascular Development in Mutant VE-Cadherin Embryos
(a and b) Hematoxylin-eosin staining of E8.25 VEC1/1 (a) and VEC2/2 (b) embryos, revealing assembly of endothelial cells in primitive vessels
(arrowheads).
(c, d, and g±j) Vascular development at E8.5 (PECAM immunostaining). As compared to VEC1/1, mutant embryos exhibit the following features:
the aorta (Ao) and common cardinal vein (CCV) (c and d) and the yolk sac capillaries (i and j) are assembled, but the lumen in the thoracic
aorta and anterior cardinal vein (ACV) is smaller (g and h); the cephalic vascular plexus contains irregular and dilated vessels (arrowheads in
[c] and [d]); and the endocard (EC) is discontinuous and scrambled (g and h).
(e, f, and k±p) The vasculature ([e] and [f], JAM immunostaining; rest, PECAM immunostaining) in E9.0 and E9.25 VEC1/1 embryos (e and k),
yolk sacs (m), and placenta (o) matured into a branching network of large and small vessels with a well-formed aorta (Ao in [e] and [k]),
common cardinal veins (CCV in [e]), sprouting intersomitic vessels (ISV in [e]), vitello-embryonic vessels (VE in [m]) and a placental labyrinth
zone (between arrowheads in [o]) rich in embryonic vessels (EV in [o]) intermingled with maternal lacunae (ML in [o]), all containing an intact
endothelial lining (inset in [m]). In contrast, the vasculature in mutant embryos (f and l), yolk sacs (n) and placenta (p) disintegrated, as revealed
by the presence of only a few scrambled endothelial cells in the aortic sac (AS; panel [l]), the dilatation of the cephalic veins (arrowheads;
panel [l]), the disappearance of endothelial cells in the thoracic dorsal aorta (Ao; panel [l]) or in vitelline vessels (inset in [n]), the loss of
connections between yolk sac vessels at their branches (n), and the failure of embryonic vessels (EV) to invade deeply in the placenta (p).
(q±r) Injection of VE-cadherin antibodies in E8.5 embryos induced vascular defects (r) whereas vascular development was normal after injection
of control IgGs (q).
Magnification bar is 100 mm in (a), (b), (g)±(l), and (o)±(r); and 200 mm in the other panels.
mice, were born at the expected frequency for Mende- E9.0, mutant embryos became progressively growth re-
tarded, contained smaller pharyngeal arches, and hadlian inheritance. Intercrossing of VEC1/2, VEC1/neo, or
VEC1/dC mice did not yield viable VEC2/2, VECneo/neo, or fewer somites than VEC1/1 embryos (11 6 1.5 in VEC2/2;
13 6 0.8 in VECneo/neo; 14 6 0.7 in VECdC/dC; 16 6 0.4 inVECdC/dC offspring, respectively, indicating that complete
loss or homozygous expression of a truncated VE-cad- VEC1/1; p , 0.05 VEC1/1 versus others; Figures 2e and
2f). Mutant VE-cadherin embryos failed to progress be-herin induced embryonic lethality. Mutant embryos were
recovered at E8.5 and E9.5 at the expected Mendelian yond a developmental stage of E8.75±E9.0 and invari-
ably died beyond E9.5.frequency (25%, 24%, and 26% of 310 VEC2/2, 450
VECneo/neo, and 280 VECdC/dC embryos, respectively) but
died at E9.5±E10. VEC2/2, VECneo/neo, and VECdC/dC em- Role of VE-Cadherin in Vascular Development
Histologic analysis and immunostaining for platelet en-bryos exhibited the same phenotype, described below.
VEC1/1 and mutant embryos initially contained a similar dothelial cell adhesion molecule type-1 (PECAM/CD31)
and junctional adhesion molecule (JAM) indicated thatnumber of somites at E8.5 (Figures 2c and 2d), but by
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Figure 3. Endothelial Apoptosis in Mutant VE-Cadherin Embryos
(a±d) Transmission electron micrographs of E9.0 embryonic vessels, revealing an intact lining of endothelial cells (EC) in a VEC1/1 vessel (a),
in contrast to numerous gaps between mutant endothelial cells (arrowheads in [b]). VEC1/1 endothelial cells adhered to each other via well-
developed intercellular junctions over a long distance (arrowheads in [c]); junctional complexes were found between mutant cells, but less
frequently and over short distances (arrowhead in [d]).
(e and f) Laminin immunostaining revealing firm attachment of endothelial cells in E9.0 VEC1/1 vessels (e) and endothelial detachment from
the basement membrane in VEC2/2 embryos (f).
(g) Transmission electron micrograph of an apoptotic endothelial cell (arrowheads) in a mutant vessel.
(h and i) Scanning electron micrographs of the outflow tract of E8.75 embryos, revealing an intact and continuous endocard (EC) lining a
ventricular cavity and a normal myocard (My) in VEC1/1 embryos (h) but an endocardium that is detached, lies scattered in the center, occludes
the ventricular lumen, and is surrounded by a loose and disorganized myocardium in mutant embryos (i).
(j and k) TUNEL staining, revealing apoptotic endothelial cells (arrowheads) in mutant (k) but not in VEC1/1 (j) vessels. Ao, aorta; VV, vitelline
vein; UV, umbilical vein.
(l and m) TUNEL-positive endothelial cells in hearts from adult wild-type mice are absent after injection of control antibodies (l) but numerous
after injection of VE-cadherin antibodies (arrowheads in [m]).
(n and o) Nuclear p53 immunostaining was absent in wild type (n) but detectable in mutant yolk sacs (o).
(p and q) p21 immunostaining in myocardial endothelial cells was absent after injection of control antibodies (p) and detectable after injection
of VE-cadherin antibodies (q).
Magnification bar is 1 mm in (c) and (d); 5 mm in (a) and (b); 10 mm in (g) and (l)±(q); 20 mm in (e), (f), and (k); and 50 mm in (h)±(j).
absent or truncated VE-cadherin did not prevent in situ (thoracic dorsal aorta, anterior cardinal vein; Figures 2g
and 2h) whereas others were dilated (cephalic vessels).differentiation of angioblasts to endothelial cells (Figure
2). In addition, mutant endothelial cells expressed com- In mutant embryos, endothelial cells in the yolk sac
formed channels that started to disconnect from eachparable amounts of endothelial markers (see Supple-
mental Data below) and N-cadherin (Figure 1f), and pro- other at their branches (Figures 2i and 2j), whereas endo-
cardial cells detached from each other and lay scatteredduced laminin (Figures 3e and 3f), collagen IV, and the
tight junctional molecule zona occludens (ZO)-1 (not in the ventricular cavity (Figures 2g and 2h). The lack
of yolk sac±derived red blood cells inside E8.5 VEC1/1shown). VEC1/1 and mutant embryos were indistinguish-
able at E8.0, i.e., immediately after onset of angioblast embryos indicated that the vitello±embryonic circulation
was not yet established.formation (not shown). By E8.25±E8.5, angioblasts in
both VEC1/1 and mutant embryos differentiated to endo- Vascular defects in mutant VE-cadherin embryos were
more severe beyond E8.75±E9.0, when the primitive vas-thelial cells that became assembled in primitive vessels
within the embryo and yolk sac (Figures 2a±2d), indicat- cular network in VEC1/1 embryos expands via sprouting
angiogenesis and remodels in a branching network ofing that initial vasculogenesis occurred after loss/trun-
cation of VE-cadherin. However, by E8.5, certain vessels large and small vessels. Endothelial cells throughout the
entire vasculature progressively became disconnectedin mutant embryos had a minimal or even no lumen
VE-Cadherin and VEGF-Induced Endothelial Survival
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from each other and exhibited numerous gaps (Figures Endothelial Cell±Cell Junctions
VEC1/1 endothelial cells expressed molecules, present3a and 3b), detached from their underlying basement
membrane (Figures 3e and 3f), and lay scattered inside in tight junctions (JAM, ZO-1, occludin, cingulin), ad-
herens-type junctions (VE-cadherin, b-catenin), or unre-the lumen (Figures 2g, 2h, 2k, and 2l; endocardial cells
in Figures 3h and 3i). Several of these endothelial cells lated to junctional complexes (PECAM, N-cadherin) (Fig-
ure 1f; Figure 2; Figures 4a, 4c, and 4e; not shown).were apoptotic, as evidenced by terminal deoxytransfer-
ase-mediated deoxyuridine nick end-labeling (TUNEL) Mutant endothelial cells expressed comparable amounts
of N-cadherin, JAM, ZO-1, cingulin, and PECAM (Figure(Figures 3j and 3k), annexin V staining, and transmission
electron microscopy (Figure 3g). Sprouting of intersomi- 1f; Figure 2; Figures 4b and 4f; not shown) indicating
that loss or truncation of VE-cadherin did not inducetic vessels (Figures 2e and 2f) and remodeling into a
network of large and small branches was impaired in compensatory upregulation of these junctional mole-
cules. In mutant cells, b-catenin was slightly reducedmutant embryos and yolk sacs, often resulting in irregu-
lar, dilated vessels (cephalic vessels; Figures 2k and 2l). (Figure 1f) and not clustered at cell±cell contacts (Fig-
ures 4c and 4d) but associated with N-cadherin. MutantOther vessels were present as cords with a minimal
lumen (pharyngeal arch vessels), contained few discon- endothelial cells were attached to each other by electron
dense junctions (Figures 3c and 3d) that contained adhe-nected and scattered endothelial cells (outflow tract;
Figures 2k and 2l; vitelline vessels; inset in Figures 2m sive proteins found in tight junctions including JAM (Fig-
ure 2f) and ZO-1 and occludin (not shown). However,and 2n), progressively disconnected from each other at
branches, thereby inducing stagnating blood lakes (yolk these intercellular contacts were less frequent, occurred
over shorter distances, and were too weak to maintainsac; Figures 2m and 2n), or regressed (thoracic dorsal
aorta; Figures 2k and 2l; vitelline and umbilical vessels). an intact endothelial lining, resulting in numerous gaps
between endothelial cells (Figures 3a and 3b).In VEC1/1 placentas, allantoic vessels invaded the chorion
by E8.5 and formed a labyrinth layer, in which embryonic
vessels lay closely apposed to maternal lacunae by E9.5 Neutralization of VE-Cadherin in Cultured Embryos
(Figure 2o). In contrast, although mutant embryonic en- Neutralization of VE-cadherin in cultured VEC1/1 em-
dothelial cells invaded the chorion, they failed to pene- bryos using antibodies, that prevent clustering of VE-
trate in the trophoblast layer and never established close cadherin, confirmed the findings in mutant embryos.
interactions with the maternal sinuses (Figure 2p). As a Injection of control or VE-cadherin antibodies in E7.5
result, mutant placentas only contained a spongiotro- embryos (e.g., at the onset of hemangioblast and endo-
phoblast but not a labyrinth zone, remained much thin- card formation) did not prevent in situ differentiation of
ner (300 6 40 mm in VEC1/1 versus 110 6 15 mm in endothelial cells nor their assembly in vessels or in an
VEC2/2 at E9.5; p , 0.05), and did not develop beyond intact endocardium (see Supplemental Data below). In-
the E8.75 stage. stead, intracardial injection at E8.5 (e.g., when primitive
Beyond E9.25, vessels in mutant VE-cadherin em- vessels were already assembled) of VE-cadherin but
bryos regressed, disintegrated, and collapsed (Figures not of control antibodies (or vehicle) caused abnormal
2e and 2f), causing circulatory insufficiency and progres- remodeling of the vasculature with formation of blood
sive necrosis. Thus, normal VE-cadherin function is not lakes in the yolk sac, dilatation of head mesenchyme
or only minimally required for assembly into a primitive vessels, and detachment of the endocardium and other
capillary plexus (vasculogenesis) but is essential for endothelial cells (Figures 2q and 2r). Thus, VE-cadherin
subsequent expansion, maturation, branching and re- is not required for initial endothelial assembly but is
modeling into a network of veins and arteries of different essential for normal vascular integrity and expansion/
sizes (angiogenesis), and prevention of vascular regres- remodeling, even after a primitive vascular network is
sion. A more detailed description of the mutant vascula- established.
ture can be found in the Supplemental Data (see below). Culturing of 3.5-day-old VEC1/1 blastocysts into yolk
sac cysts allowed differentiation of hemangioblasts into
endothelial cells that subsequently assembled in primi-
Endothelial/Mural Cell Interactions in Mutant tive vessels. Endothelial cells also assembled in capillar-
VE-Cadherin Embryos ies in VEC2/2 yolk sacs as well as in VEC1/1 yolk sac
Heart tubes in VEC1/1 embryos looped at E8.75 and cysts treated with VE-cadherin antibodies. During pro-
formed distinct chambers by E9.5, when the ventricular longed culture, capillaries enlarged in VEC1/1 yolk sacs
myocardium formed finger-like trabecular protrusions, but regressed in VEC2/2 yolk sacs. Again, in this culture
lined by an intact endocardium. In mutant embryos, car- model, VE-cadherin function is not required for assem-
diac looping occurred but chamber development and bly of endothelial cells in vessels but is essential for their
trabeculation were impaired. Scanning electron micros- further expansion and maintenance. A more detailed
description of vascular development in blastocyts cancopy revealed scattered, disconnected endocardial cells
be found in the Supplemental Data (see below).and a disorganized, loosely assembled myocardium
(Figures 3h and 3i). Since endocardial defects preceded
myocardial defects, and VE-cadherin was only detect- Role of VE-Cadherin in the Endothelial Survival
able in endocardial but not in myocardial cells, the ab- Activity of VEGF
normal cardiac development most likely resulted from The mechanism via which VE-cadherin causes endothe-
endocardial defects. A more detailed description of lial dysfunction was further studied. Differentiation of
heart development in mutant embryos can be found in mutant endothelial cells was not impaired as suggested
by the comparable expression of several endothelialthe Supplemental Data (see below).
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Figure 4. Expression of Junctional Proteins and Interaction of VE-Cadherin with VEGFR-2
(a±h) Immunofluorescent staining of cultured VEC1/1 (a, c, e, and g) or VECdC/dC (b, d, f, and h) endothelial cells for VE-cadherin (a and b),
b-catenin (c and d), JAM (e and f) and VEGFR-2 (g and h), which were all clustered at junctions in VEC1/1 cells. In contrast, b-catenin and
VEGFR-2 were absent from endothelial junctions in VECdC/dC cells. The residual white spots in (d) represent background.
(i and j) Immunogold labeling revealing VEGFR-2-labeled gold particles (arrowheads) at endothelial junctions from E9.0 VEC1/1 (i) but not
VECdC/dC (j) embryos.
(k±m) Immunoprecipitation of cultured endothelial cells with antibodies to VEGFR-2 (k), VEGFR-3 (l), or VEGFR-1 (m) and subsequent Western
blotting for the indicated proteins. VE-cad, VE-cadherin; PI3K, PI3-kinase. VEGFR-1 and VEGFR-2 exist as two different glycosylation forms;
three VEGFR-3 polypeptides were detected: a 170 kDa precursor, a 190 kDa mature form, and a proteolytically cleaved 120 kDa form.
(n) Western blotting for phosphorylated (phospho-Akt) and total Akt in HUVEC cells without (2) or with VEGF-A in the presence of control or
VE-cadherin IgG antibodies.
(o) Proposed model of the role of VE-cadherin in VEGF-A-mediated survival of endothelial cells. Via formation of a multicomponent junctional
complex between VE-cadherin, b-catenin (b-cat), PI3-kinase (PI3K), and VEGFR-2, VE-cadherin promotes VEGF-A-mediated activation of Akt
and endothelial survival.
Magnification bar is 1 mm in (i) and (j); 5 mm in (g) and (h); and 10 mm in (a)±(f).
receptors (see Supplemental Data below). Proliferation the absence of serum, VECdC/dC endothelial cells exhib-
ited increased apoptosis, measured as the number ofof endothelial cells in E9.0 yolk sacs was also similar
(percent BrdU-positive cells: 20% 6 2% in VEC1/1; TUNEL-positive cells (not shown) or as the amount of
oligonucleosomes (Table 1). Notably, the endothelial23% 6 4% in VECneo/neo; 22% 6 2% in VEC2/2; and 25% 6
2% in VECdC/dC). However, there were fewer endothelial survival factor VEGF-A rescued survival of VEC1/1 but
not of VECdC/dC endothelial cells (Table 1), even thoughcells in E9.0 mutant than in VEC1/1 yolk sacs (cells/mm
sectioned yolk sac: 6 6 2 in VECneo/neo; 7 6 1 in VEC2/2; the latter cells expressed similar amounts of the VEGF-A
receptor VEGFR-2 (Figure 4k). In contrast, basic fibro-8 6 1 in VECdC/dC; and 23 6 2 in VEC1/1; p , 0.05 versus
VEC1/1). The endothelial defects were not due to re- blast growth factor (bFGF) rescued endothelial survival
regardless of the presence or absence of VE-cadherinduced expression of the angiogenic factors VEGF-A or
VEGF-C (see Supplemental Data below). Therefore, vas- (Table 1). The survival function of VE-cadherin was spe-
cific for VEGF-A, as other VEGF-A homologs includingcular defects were most likely attributable to impaired
endothelial survival. VEGF-C and VEGF-D (which bind VEGFR-3 and, less
avidly, VEGFR-2) and placental growth factor (PLGF;When polyomavirus middle-T antigen-immortalized
VEC1/1 and VECdC/dC endothelial cells were cultured in which only binds VEGFR-1) had no effect on endothelial
VE-Cadherin and VEGF-Induced Endothelial Survival
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Table 1. Effect of Growth Factors on Apoptosis, Bcl2, p53, and p21 in Immortalized Endothelial Cells
Oligo-nucleosomes
(per 105 cells) Bcl2 (U/105 cells) p53 (pg/105 cells) p21 (pg/105 cells)
Growth Factors VEC1/1 VECdC/dC VEC1/1 VECdC/dC VEC1/1 VECdC/dC VEC1/1 VECdC/dC
None 54 6 3 160 6 9 110 6 10 33 6 7 0.9 6 0.1 1.6 6 0.3 0.9 6 0.1 1.9 6 0.4
VEGF-A 20 6 2* 190 6 11 160 6 8* 42 6 6 0.4 6 0.1* 1.1 6 0.3 0.5 6 0.1* 1.2 6 0.3
VEGF-A 1 wortmannin 60 6 5 180 6 16 ND ND ND ND ND ND
VEGF-A 1 LY294002 67 6 6 180 6 19 ND ND ND ND ND ND
bFGF 11 6 1* 47 6 2* 155 6 7* 90 6 7* 0.4 6 0.1* 0.6 6 0.2* 0.6 6 0.1* 0.6 6 0.2*
PLGF 63 6 4 190 6 18 ND ND ND ND ND ND
VEGF-C 64 6 9 180 6 13 ND ND ND ND ND ND
VEGF-D 64 6 9 180 6 8 ND ND ND ND ND ND
Values represent mean 6 SD of at least six measurements. Growth factors were supplemented at 100 ng/ml; wortmannin and LY294002, at
100 nM. (*) p , 0.05 versus control without growth factors by unpaired t test. ND, not determined.
survival (Table 1), even though VEGFR-1 and VEGFR-3 by VEGF-A in VEC1/1 but not in VECdC/dC cells (800 control
and 1100 after VEGF-A in VEC1/1 cells versus 450 controlwere present (Figures 4l and 4m). The VE-cadherin/
VEGF-A interaction was not restricted to immortalized and 300 after VEGF-A in VECdC/dC cells; the constitutive
activation of Akt by polyomavirus middle T-antigen usedmurine endothelial cells, as treatment of freshly isolated
human umbilical vein endothelial cells (HUVEC) or of the for cell immortalization [Meili et al., 1998] most likely
impaired Akt induction in response to VEGF-A). Totalendothelial cell line 1G11 with VE-cadherin antibodies
also abolished VEGF-A survival function. In addition, Akt was immunolocalized in endothelial cells in VEC1/1
and mutant embryos but, due to lack of suitable antibod-intravenous injection of VE-cadherin antibodies in adult
wild-type mice, which leads to loss of vascular integrity ies, phospho-Akt could not be immunolocalized in vivo
(see Supplemental Data below). Despite the presenceand endothelial detachment in the heart (Corada et al.,
1999), significantly increased the number of TUNEL- of VEGFR-3 in the VE-cadherin complex, VEGF-C did
not affect endothelial apoptosis (Table 1) nor Akt phos-positive endothelial cells per mm2: 1 6 1 after injection
of control antibodies versus 230 6 20 after injection of phorylation (densitometry levels: 800 control and 600
after VEGF-C in VEC1/1 versus 610 control and 550 afterVE-cadherin antibodies (p , 0.05 versus control anti-
bodies) (Figures 3l and 3m). VEGF-C in VECdC/dC). Thus, a multicomponent complex
comprising VE-cadherin, b-catenin, VEGFR-2, and PI3-
kinase appears to be required for the endothelial survivalVE-Cadherin/b-Catenin Signaling in
PI3-Kinase/Akt-Mediated Survival function of VEGF-A through activation of Akt. Disruption
of this complex by truncation of VE-cadherin (whichVEGF-A is a survival factor for endothelial cells via acti-
vation of VEGFR-2 and subsequent signaling of PI3- abolishes association with b-catenin) or by VE-cadherin
antibodies (which prevents clustering of VE-cadherin)kinase (Gerber et al., 1998b). The PI3-kinase inhibitors
wortmannin and LY294002 blocked VEGF-A-mediated renders endothelial cells refractory to the VEGF-A sur-
vival signal (Figure 4o).survival of VEC1/1 endothelial cells but did not affect
apoptosis of VECdC/dC endothelial cells when cultured in
the absence of serum (Table 1). Immunofluorescent and Role of p53/p21 and Bcl2 in VE-Cadherin-Mediated
Endothelial Survivalimmunogold labeling revealed that VEGFR-2 was pres-
ent at intercellular junctions in VEC1/1 cells but not in Endothelial apoptosis has been associated with down-
regulation of Bcl2 and upregulation of the proapoptoticmutant endothelial cells (Figures 4g±4j). Coimmuno-
precipitation experiments revealed an association be- mediator p53 and its target p21 (Stromblad et al., 1996;
Gerber et al., 1998a). VEGF-A increased the levels oftween VE-cadherin, b-catenin, PI3-kinase and VEGFR-2
in VEC1/1 but not in VECdC/dC cells, notwithstanding com- Bcl2 and reduced those of p53 and p21 in VEC1/1 but
not in VECdC/dC cells, when cultured in the absence ofparable levels of VE-cadherin, VEGFR-2, PI3-kinase,
and b-catenin (Figure 4k). Similar results were ob- serum (Table 1). In contrast, bFGF increased the levels
of Bcl2 and reduced those of p53/p21 in both genotypestained when cell extracts were immmunoprecipitated
with PI3-kinase, b-catenin, or VE-cadherin antibodies (Table 1). Treatment of serum-starved HUVEC cells with
VE-cadherin but not with control antibodies also re-(not shown). VEGFR-3, but not VEGFR-1, also coimmu-
noprecipitated with VE-cadherin in VEC1/1 but not in duced Bcl2 and increased p53/p21 levels and abrogated
the survival effect of VEGF-A but not of bFGF (see Sup-VECdC/dC cells (Figures 4l and 4m).
In contrast to PLGF, VEGF-A induces PI3-kinase activ- plemental Data below). p53 and p21 immunoreactivity
were detected in mutant but not in VEC1/1 endotheliality, known to result in phosphorylation of Akt (Gerber
et al., 1998b). VEGF-A increased phospho-Akt levels cells in E9.0 yolk sacs (Figures 3n and 3o) and in adult
myocardial endothelial cells after intravenous injectionz4-fold in HUVEC cells treated with control but not with
VE-cadherin antibodies, despite similar total Akt kinase of VE-cadherin but not of control antibodies (Figures 3p
and 3q). In addition, p21 mRNA transcripts, determinedlevels (arbitrary densitometric units: 720 control and
2100 after VEGF-A for control antibodies versus 660 by quantitative real-time RT-PCR, were higher in mutant
than in VEC1/1 yolk sacs (copies p21 per 1000 copiescontrol and 740 after VEGF-A for VE-cadherin antibod-
ies; Figure 4n). Phospho-Akt levels were also increased hprt: 340 6 30 in VEC2/2 versus 180 6 19 in VEC1/1 at
Cell
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E8.75; 200 6 40 in VEC2/2 versus 100 6 9 in VEC1/1 at embryos may be due to insufficient endothelial adhe-
sion, most vascular defects in mutant embryos ap-E9.5; p , 0.05). No differences were observed in p53
mRNA transcript levels (copies p53 per 1000 copies peared attributable to impaired intracellular signaling.
This is suggested by appearance of vascular defects inhprt: 2100 6 200 in VEC1/1 versus 2300 6 240 in VEC2/2
at E8.75; p 5 NS), suggesting that p53 levels may be mutant embryos before onset of flow (E8.5) or in the
absence of vitello-embryonic circulation (.E8.75), byregulated posttranscriptionally. Mice deficient in p53 or
p21 contained fewer TUNEL-positive endothelial cells abnormal expansion and remodeling into a mature vas-
cular network, by impaired sprouting, by vessel regres-than wild type mice after intravenous injection of VE-
cadherin antibodies (TUNEL-positive endothelial cells/ sion, by reduced endothelial survival, and, most notably,
by the similar phenotype of embryos completely lackingmm2 were 230 6 20 in wild type, 160 6 15 in p532/2,
p , 0.05 versus wild type; and 95 6 20 in p212/2, p , or expressing a truncated VE-cadherin.
Loss or truncation of VE-cadherin did not impair endo-0.05 versus wild type).
thelial proliferation or differentiation, but increased en-
dothelial apoptosis due to an inability of VE-cadherinHematopoiesis
deficient cells to respond to the survival activity ofLoss or truncation of VE-cadherin did not significantly
VEGF-A. The latter is known to mediate endothelial sur-impair hematopoiesis in E8.5 yolk sacs, as comparable
vival via binding to VEGFR-2, thereby activating PI3-numbers of nucleated blood cells were present in blood
kinase and Akt (Nunez and del Peso, 1998) and via in-islands in vivo, and a similar number of hematopoietic
creasing the levels of the antiapoptotic mediator Bcl2progenitors was present in yolk sacs: the number of
(Gerber et al., 1998a, 1998b). VE-cadherin appears toerythroid (BFU-E), myeloid (CFU-GM), or mixed (CFU-
be required for these VEGF-A-dependent survival sig-mix) colonies per 104 yolk sac cells was 34 6 8, 18 6
nals through formation of a VE-cadherin/b-catenin/7, and 37 6 10 in VEC1/1 yolk sacs and 33 6 7, 23 6
PI3-kinase/VEGFR-2 complex. Interestingly, one of the7, and 38 6 10 in VEC2/2 yolk sacs (p 5 NS).
first signs of endothelial apoptosis is rapid cleavage
of VE-cadherin and b-catenin (Brancolini et al., 1997;Supplemental Data
Herren et al., 1998), which might represent an amplifica-Due to space restrictions, supplemental data (http://www.
tion mechanism to the death response.cell.com/cgi/content/full/98/2/147/DC1) provide more
Previous studies have implicated nuclear signaling ofdetailed information on the description of the cardiovas-
b-catenin in apoptosis but its role remains controversial.cular development in mutant embryos, on the expres-
Indeed, reduced stabilization of free cytosolic b-catenin,sion of endothelial markers and angiogenic candidates,
due to impaired interaction with mutated presenilin, ap-on vascular formation in cultured embryos and blasto-
peared to potentiate neuronal apoptosis (Zhang et al.,cysts, on the immunolocalization of Akt, and on Bcl2
1998) whereas increased Drosophila b-catenin, com-and p53/p21 levels in mutant endothelial cells.
plexed with Tcf, activated apoptosis (Ahmed et al.,
1998). In the present study, b-catenin levels were slightlyDiscussion
reduced in VEC2/2 and VECdC/dC endothelial cells, and
the ratio of b-catenin bound to VE-cadherin relative toAlthough several adhesive molecules attach vascular
that present in the cytoplasm or the nucleus did notcells to each other, VE-cadherin plays a unique, essen-
change in antibody-treated VEC1/1 cells (not shown),tial role in this process, since loss or truncation of VE-
rendering it unlikely that susceptibility to apoptosis wascadherin prevents normal vascular development. This
due to increased levels of free b-catenin.is unexpected, as N-cadherin also has strong adhesive
Refractoriness of endothelial cells to VEGF-A survivalproperties (Radice et al., 1997) and is associated with
signals may largely explain the mutant phenotype. Oncethe same set of proteins in mutant endothelial cells.
endothelial cells are assembled and organized in primi-The present study confirms the well-known role of VE-
tive vessels, subsequent remodeling and pruning of thecadherin in mediating interendothelial adhesion but in
primitive vascular labyrinth may require endothelial apo-addition unveils a novel role for this molecule in control-
ptosis. The present study demonstrates that VE-cad-ling VEGF-A-mediated endothelial survival, via a path-
herin is not essential during initial vessel assembly butway involving the cytoplasmic domain of VE-cadherin,
that it regulates endothelial apoptosis during the secondb-catenin, PI3-kinase, and VEGFR-2.
phase of angiogenesis. Interestingly, the role of VE-Loss or truncation of VE-cadherin was expected to
cadherin is specific for VEGF-A and not for bFGF, aabort vascular development in its earliest stage in vivo,
pleiotrophic factor that also affects nonendothelial cells,as VE-cadherin-deficient endothelial cells failed to orga-
thereby rendering the VEGF-A/VE-cadherin responsenize in vessel-like patterns, at least in an artificial em-
highly restricted to endothelial cells. The expression ofbryoid body system in vitro (Vittet et al., 1997). However,
VEGFR-2 and VE-cadherin in all endothelial cells and ofour data demonstrate that neither VE-cadherin nor the
VEGF-A in the surrounding mesenchyme in the E8.5±stabilization of the adherens-type junctions, which de-
E9.5 embryo (Breier et al., 1995, 1996) underscores thepends on the interaction of the VE-cadherin tail with the
role of VE-cadherin in controlling the VEGF-A/VEGFR-2cytoskeleton, is required for initial assembly of endothe-
survival function during vascular development.lial cells in vivo. This may relate to the minimal hemody-
The role of VEGFR-3 clustered to VE-cadherin in thenamic stress before onset of the circulation and/or to
junction and its relevance for the present phenotype isthe presence of other adhesive molecules at interendo-
less obvious. Indeed, although VEGFR-3 codistributedthelial contacts.
Although enlargement of certain vessels in mutant with VE-cadherin in junctions, VEGF-C did not affect
VE-Cadherin and VEGF-Induced Endothelial Survival
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al., 1996b; Rosen et al., 1997; Esser et al., 1998; Hogers et al., 1999).endothelial survival nor Akt phosphorylation. Further-
For immunostaining of VEGFR-2, cultured cells were fixed in 2208Cmore, VEGFR-3 expression is restricted to the venous
methanol (3 min), permeabilized with saponin (15 min), and incu-endothelium and absent in the dorsal aorta, the endo-
bated with 0.5% BSA±0.1% saponin in PBS before incubation with
card, and yolk sac endothelial cells (Kukk et al., 1996), antibodies. The following antisera were used: rat anti-CD31/PECAM
which were all affected in mutant embryos. Perhaps, (clone MEC7.46), rat anti-VE-cadherin (clone 19E6), rat anti-JAM
(clone BV11), mouse anti-desmin (ICN Pharmaceuticals #10519, Costajunctional VEGFR-3 requires other signals for survival
Mesa, CA), rabbit anti-laminin (Sigma), mouse anti-b-catenin (cloneor could be involved in other processes.
14) and anti-ZO-1 (both from Transduction Laboratories, Lexington,Endothelial apoptosis is increasingly recognized as a
KY), rabbit anti-N-cadherin and rabbit anti-pancadherin (both giftpossible mechanism of action of angiogenesis inhibitors
from Dr. Geiger), rabbit anti-mouse Akt (NEB, Beverly, MA), rabbit
such as avb3 antagonists, thrombospondin, angiostatin, anti-mouse p53 (Novo Castro #CMTp, Newcastle, UK), rabbit anti-
endostatin, etc. (Stromblad et al., 1996). Nevertheless, p21/WAF (Oncogene Research Products #PC55, Cambridge, MA).
Mouse monoclonal antibodies were biotinylated.the intracellular signals mediating endothelial apoptosis
remain incompletely understood. The upregulation of
p53/p21 in apoptosis-prone VE-cadherin-deficient en- Culture of Embryos and Endothelial Cells
dothelial cells suggests a possible causal role of these Methods for culturing E7.5 and E8.5 embryos have been described
(Rosen et al., 1997; Van Maele-Fabry et al., 1997), except that asignals in endothelial apoptosis. However, since endo-
culture medium consisting of 50% DMEM and 50% rat serum wasthelial apoptosis in response to immunoneutralizing VE-
used for E7.5 embryos. Fifty nanoliters (E7.5) or 100 nl (E8.5) Hanks'cadherin antibodies was only partially reduced in p532/2
balanced salt solution (HBSS; vehicle) containing 100 mg/ml anti-
or p212/2 mice, other proapoptotic pathways may be bodies was injected in the region immediately anterior to the right
implicated as well. cardiogenic mesoderm (E7.5) or intracardially (E8.5) (Rosen et al.,
An intriguing issue is whether VE-cadherin also exerts 1997). Noninjected E7.5 embryos were also cultured in medium
containing 100 mg/ml control or VE-cadherin antibodies. After 16a survival or maintenance function for adult quiescent
(E7.5) or 8 (E8.5) hr of culture, embryos were processed for histology.endothelium or during pathological angiogenesis. The
Preimplantation blastocysts (3.5 days old) were cultured under con-constitutive life-long expression of VE-cadherin, in addi-
ditions supporting their development into yolk sac cysts as de-
tion to our present data that VE-cadherin antibodies scribed (McClanahan et al., 1993). Differentiation of ES cells to endo-
induce endothelial apoptosis in adult mice, would in- thelial cells and enrichment of endothelial cells were performed as
deed support such a role. In conclusion, loss of VE- described (Vittet et al., 1996). Immortalized endothelial cell lines
were generated by transduction of endothelial cells, obtained bycadherin or lack of binding of b-catenin via truncation
flow-cytometric enrichment of differentiated ES cells, with a retrovi-of its cytoplasmic tail prevents vascular development
rus expressing the Polyoma middle-T oncogene (Bussolino et al.,due to an impaired response of endothelial cells to
1991). Alternatively, E9.0 embryos were enzymatically dispersed
VEGF-A survival signals. The data implicate a novel role using collagenase A (1.5 mg/ml; Boehringer Mannheim, Germany)
for VE-cadherin/b-catenin in intracellular signaling by and subsequently infected with the Polyoma middle-T retrovirus.
clustering proteins involved in VEGF-A survival sig- Endothelial cells were routinely cultured on 0.1% gelatin-coated
dishes in DMEM with 20% fetal calf serum (Life Technologies, Pais-naling.
ley, UK), supplemented with endothelial cell growth supplement (50
mg/ml; Life Technologies) and heparin (100 mg/ml; Sigma) (Esser etExperimental Procedures
al., 1998).
Generation of Transgenic Mice
pPNT.VECnull contained a 3.1 kb BglII fragment, a floxed neo cas- Apoptosis and Proliferation
sette, and a 5.5 kb XbaI/EcoRV fragment (Figure 1a). pPNT.VECdC For apoptosis, endothelial cells were seeded at 2.4 3 105 cells for
contained a 5.8 kb XbaI/EcoRI fragment, a floxed neo cassette, and a 24 hr in 24-well dishes in 0.5 ml of serum-free MCDB 131 medium
2.1 kb EcoRI fragment. The oligonucleotide TTAGTCTAGATGGGCC (Life Technologies, Paisley, UK) supplemented with 1% bovine se-
(stop codon, bold; XbaI site, underlined) was inserted at nucleotide rum albumin (BSA) and ITS (Life Technologies). The culture was con-
2141 of the VE-cadherin cDNA (Figure 1a). The following primers tinued for 96 hr either in the absence or in the presence of VEGF-A
were used for PCR genotyping: VEC1, 59-GTC CAA CGT GAA CCG or PLGF (R&D Systems, MN; 30±100 ng/ml), bFGF (R&D; 50 ng/
CCA GAA TGC TAA-39; VEC2, 59-GAC ATC TCT GGC ACA GAT GCG ml), or VEGF-C (100 ng/ml; gift of K. Alitalo). Antibody to VE-cadherin
TTG AAT-39; PGKpA, 59-AAT GTG TCA GTT TCA TAG CC-39; VEC3, (clone BV13) or control antibody (both at 50 mg/ml) were added 24
59-ACC GTG GGT GTG TGC AAG-39; VEC4, 59-AGT GAA TTC TTT hr after seeding, and daily thereafter. Apoptosis was quantified by
CTT CAC GTC GAT CAT GGT G-39; VEC5, 59-CTG TTG CTC TGA measuring cytoplasmic histone±associated DNA fragments (mono-
CTT GCA GTG ATT TTG CTG AT-39; VEC6, 59-GGC CAT CTC CCT and oligonucleosomes) or TUNEL, and Bcl2 (U/105 cells), p21 (U/105
GGG CCC ATC TAG ACT AA-39; VEC7, 59-GCC TGG ACT GCA CGG cells), and p53 (pg/105 cells) were quantified as described (Carmeliet
AGG GCC CAG GGA G-39; VEC8, 59-TCT CAC TCT TCC AGT TTT et al., 1998). Apoptosis in embryos was visualized by TUNEL or
TGG AGT GGC-39 (Figures 1a and 1b). VECdC/dC mice were generated annexin V immunostaining after intracardiac injection of 100 nl AnX-
by crossbreeding VEC1/neo mice with pgk:cre mice (Lallemand et al., biotin (Apoptest-biotin; Nexins Research B. V., Hoeven, The Nether-
1998). All methods for culture, selection, identification of ES cells, lands). The number of proliferating yolk sac endothelial cells was
and generation of transgenic mice have been described (Carmeliet expressed as percent of total (Carmeliet et al., 1996a). Antibody
et al., 1996a; Rosen et al., 1997). Western blotting and quantitative injections in adult mice was done as described (Corada et al., 1999)
real-time RT-PCR was performed as described (Rosen et al., 1997; and hearts were analyzed for TUNEL, p53, and p21 immunostaining
Carmeliet et al., 1999). Primers for RT-PCR were for p21, 59-GTT after 16 hr.
CCG CAC AGG AGC AAA G'3, 59-ACG GCG CAA CTG CTC ACT-39;
and for p53, 59-TTC TTC CCT CAA TAA GCT ATT CTG-39, 59-CCG
Measurement of b-Catenin, PI3-Kinase, and Akt LevelsTCA TGT GCT GTG ACT TCT T-39; probes were for p21, 59-CGT
For coimmunoprecipitation, endothelial cells (2.4 3 106 in 25 cm2TGT CTC TTC GGT CCC GTG GA-39, and for p53, 59-ACA ACT GCA
flasks) were cultured for 48 hr in MCDB 131 medium containing 1%CAG GGC ACG TCT TCG-39.
BSA, and VEGF-A (80 ng/ml) was added during the last 25 min and
pervanadate (vanadate 100 mM; hydrogen peroxide 200 mM) duringHistology, Immunostaining, and Electron Microscopy
the last 7 min. Extraction, immunoprecipitation, and Western blot-All methods for histology, immunostaining, and transmission and
scanning electron microscopy have been described (Carmeliet et ting for N-cadherin, b-catenin, VEGFR-2, VEGFR-1, VEGFR-3 (Santa
Cell
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Cruz Biotechnology, Santa Cruz, CA), PI3-K (mouse antibody; Trans- Caveda, L., Martin-Padura, I., Navarro, P., Breviario, F., Corada, M.,
Gulino, D., Lampugnani, M.G., and Dejana, E. (1996). Inhibition ofduction laboratories), and VE-cadherin were performed as de-
scribed (Esser et al., 1998). To determine Akt phosphorylation (Phos- cultured cell growth by vascular endothelial cadherin (cadherin-
5/VE-cadherin). J. Clin. Invest. 98, 886±893.poPlus Akt-Ser473 kit, NEB, Westburg, Netherlands), endothelial
cells (106 cells in 35 cm Petri dishes) were cultured and stimulated Corada, M., Moriotti, M., Thurston, G., Smith, K., Kunkel, R., Brock-
as described above, except that cells were cultured for 5 days before haus, M., Lampugnani, M.G., Martin-Padura, I., Stoppacciaro, A.,
stimulation (30±100 ng/ml VEGF-A or VEGF-C) and that pervanadate Ruco, L., et al. (1999). VE-cadherin is an important determinant of
was omitted. microvascular permeability in vivo. Proc. Natl. Acad. Sci. USA, in
press.
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